Genesis Therapeutics
Deirdre Costello is an accomplished professional in structural biology, currently serving as the Associate Director at Genesis Therapeutics since March 2025. Prior experience includes the role of Principal Scientist at Treeline Biosciences and multiple positions at Eli Lilly and Company, where Deirdre advanced from Research Scientist to Senior Research Scientist. Academic credentials include a PhD and MS in Chemical and Biomolecular Engineering from Cornell University, complemented by a BS in Chemical Engineering from University College Dublin. Deirdre's doctoral research focused on the fusion kinetics of influenza, contributing to the development of anti-fusogenic therapeutics. Additional experience includes a postdoctoral position at Harvard Medical School and instructional roles fostering engineering education for youth.
This person is not in any teams
This person is not in any offices
Genesis Therapeutics
3 followers
Genesis Therapeutics is an innovative biotechnology company engaging its proprietary molecular AI technology to transform clinical outcomes for patients. The company was founded in 2019 out of Stanford University by Evan Feinberg Ph.D., co-founded by Ben Sklaroff, and backed by Vijay Pande, Ph.D. In addition, Peppi Prasit, Ph.D. leads the Scientific Advisory Board and Leonard Bell, M.D., serves as Chair of the Board of Directors. Its team of technology trailblazers and proven drug developers are driving the discovery and development of novel small molecule drugs to treat patients suffering with severe and debilitating diseases. The company expects to develop drug candidates both internally and selectively in partnership with biopharmaceutical companies.